Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in BMI · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain
Topiramate showed no clear difference in leaving the study early: for any reason compared with placebo or no treatment (low certainty).
1 finding from 1 review
Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Nausea · people with schizophrenia with antipsychotic‐induced weight gain
Topiramate showed no clear difference in reports of nausea compared with placebo or no treatment (low certainty).
1 finding from 1 review
Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Weight Average endpoint/change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain
It is very uncertain whether metformin changes leaving the study early: for any reason compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Nausea · people with schizophrenia with antipsychotic‐induced weight gain
Metformin showed no clear difference in reports of nausea compared with placebo or no treatment (low certainty).
1 finding from 1 review
Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain
1 finding from 1 review
Participants with no exacerbations in study period · adults with chronic bronchitis or chronic obstructive pulmonary disease
Summary of findings table ‐ immunostimulant probably leads to higher number of participants with no exacerbations during the study period compared with placebo (moderate certainty).
1 finding from 1 review
Mortality (all‐cause) · adults with chronic bronchitis or chronic obstructive pulmonary disease
Summary of findings table ‐ immunostimulant showed no clear difference in mortality (all‐cause) compared with placebo (moderate certainty).
1 finding from 1 review
Respiratory‐related mortality · adults with chronic bronchitis or chronic obstructive pulmonary disease
Summary of findings table ‐ immunostimulant showed no clear difference in mortality (respiratory‐related) compared with placebo (low certainty).
1 finding from 1 review
Quality of life · adults with chronic bronchitis or chronic obstructive pulmonary disease
1 finding from 1 review
Number of participants requiring antibiotics · adults with chronic bronchitis or chronic obstructive pulmonary disease
Summary of findings table ‐ immunostimulant probably leads to lower number of participants requiring antibiotics compared with placebo (moderate certainty).
1 finding from 1 review
Side effects or other adverse events · adults with chronic bronchitis or chronic obstructive pulmonary disease
Summary of findings table ‐ immunostimulant showed no clear difference in adverse events/side effects compared with placebo (high certainty).
1 finding from 1 review
Number of runners sustaining a lower‐limb running injurya ( · healthy adults participating in recreational running
Neutral / cushioned showed no clear difference in number of runners sustaining a lower‐limb running injurya ( compared with minimalist running shoes (low certainty).
1 finding from 1 review
Runner satisfaction with footwear · healthy adults participating in recreational running
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found